Provided by Tiger Trade Technology Pte. Ltd.

SCYNEXIS Inc

0.7500
+0.04506.38%
Volume:163.04K
Turnover:119.49K
Market Cap:31.47M
PE:-1.46
High:0.7546
Open:0.7190
Low:0.7000
Close:0.7050
52wk High:1.31
52wk Low:0.5650
Shares:41.97M
Float Shares:37.57M
Volume Ratio:0.36
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5129
EPS(LYR):-0.4388
ROE:-53.29%
ROA:-28.85%
PB:0.86
PE(LYR):-1.71

Loading ...

SCYNEXIS Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Nov 01, 2025

Scynexis Is Maintained at Buy by Guggenheim

Dow Jones
·
Oct 28, 2025

Scynexis to Receive $22 Million Resolving Disagreement With GSK Over Phase 3 Mario Study; Shares Rise Pre-Bell

MT Newswires Live
·
Oct 15, 2025

GSK to Pay Scynexis $22 Million to Resolve Disagreement Over Fungal Infection Treatment Study

Dow Jones
·
Oct 15, 2025

BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study

Reuters
·
Oct 15, 2025

SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments

Reuters
·
Oct 15, 2025

Scynexis Inc - to Receive Additional $2.3 Mln for Wind-Down Activities

THOMSON REUTERS
·
Oct 15, 2025

Scynexis and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 Mario Study

THOMSON REUTERS
·
Oct 15, 2025

Scynexis Inc - GSK Payment Extends Scynexis Cash Runway to Over Two Years

THOMSON REUTERS
·
Oct 15, 2025

Scynexis Inc - to Receive $22 Mln Payment Related to Phase 3 Mario Study

THOMSON REUTERS
·
Oct 15, 2025

Scynexis Announces Positive Results From a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of Its Second-Generation Fungerp (Scy-247)

THOMSON REUTERS
·
Sep 30, 2025

Scynexis Inc: No Safety Concerns or Dose Limiting Toxicities Observed

THOMSON REUTERS
·
Sep 30, 2025

Scynexis Inc: Safety, Tolerability, and Pharmacokinetic Profile Support Continued Clinical Development of Scy-247

THOMSON REUTERS
·
Sep 30, 2025

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)

GlobeNewswire
·
Sep 30, 2025

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

TIPRANKS
·
Sep 24, 2025

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

GlobeNewswire
·
Sep 04, 2025